LeaFix Medical

LeaFix Medical specializes in developing a transcatheter solution for functional mitral valve regurgitation repair, focusing on augmentation of the anterior leaflet. The system comprises an implant and a delivery mechanism designed to expand the implant within the leaflet, enlarging the leaflet area and facilitating coaptation. The company targets patients with secondary mitral regurgitation, a condition often linked to left ventricular disease, and aims to provide a minimally invasive alternative to traditional surgical methods. LeaFix is currently in the animal trial phase, showing promising results. Co-founded by Dr. Boris Orlov, a cardiac surgeon, and Boaz Harari, an engineer with two decades of experience.